Endo Internation (ENDP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 ENDO BOULEVARD CHADDS FORD, PA 19317

Develops and markets a portfolio of branded and generic pharmaceutical products primarily for the treatment of pain, including Percocet and Percodan. The company's products are marketed primarily to wholesale drug distributors and chain and independent retail pharmacists.

Data based on most recent fiscal year report
Market Cap1.277 Billion Shares Outstanding223.31 Million Avg Volume10.555 Million
1-Yr BETA vs S&P TR1.248 Current Ratio1.02 Quick Ratio0.85
View SEC Filings from ENDP instead.
Q2 2018 All Institutions Hedge Funds 1
To trade ENDP now:
Filers who had this stock in their top 10: 3 1 (0.1%)
13F Filers holding this stock: 206 35 (3.35%)
Aggregate 13F shares on 06/30/2018: 226.023 Million 63.111 Million
Aggregate 13F shares on 03/31/2018: 219.096 Million 63.131 Million
Percent change: 3.16% -0.03%
Funds creating new positions: 31 6
Funds Adding to an existing position: 73 13
Funds closing out their position: 52 11
Funds reducing their position: 72 11
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENDP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

26.1 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership

KIMMEL ROGER H - Director

2018-08-14 S 14,000 d 120,000 indirect

KIMMEL ROGER H - Director

2018-08-14 S 12,074 d 145,277 direct

COLEMAN BLAISE - Officer EVP, CHIEF FINANCIAL OFFICER

2018-08-10 F 13,636 d 47,955 direct

NICHOL CARRIE ANN - Officer VP, CONTROLLER & CAO

2018-08-10 F 484 d 5,101 direct

PERA ANTONIO R - Officer PRESIDENT, PAR PHARMACEUTICAL

2018-08-10 F 5,585 d 34,968 direct

MALETTA MATTHEW JOSEPH - Officer EVP, CHIEF LEGAL OFFICER

2018-08-10 F 13,566 d 41,364 direct

CAMPANELLI PAUL - Director - Officer PRESIDENT, CEO

2018-08-10 F 70,180 d 342,097 direct

COUGHLIN TERRANCE J - Officer EVP, CHIEF OPERATING OFFICER

2018-08-10 F 17,758 d 175,845 direct

BARRY PATRICK A - Officer EVP & CHIEF COMMERCIAL OFFICER

2018-08-10 F 3,560 d 12,120 direct

CAMPANELLI PAUL - Director - Officer PRESIDENT, CEO

2018-07-31 A 290,476 a 1,783,199 direct
Click here to report any possible errors with this stock listing.

Elevate your investments